You are here
At a Glance
Angiochem is a clinical-stage biotechnology company developing a new class of breakthrough drugs to treat brain diseases and brain-related disorders.
Moving beyond the barrier of proof and currently in clinical and preclinical studies, these novel pharmaceuticals are composed of small molecules and biologics designed to treat brain cancer, Parkinson's disease, type 2 diabetes/obesity, pain, and other unmet medical needs.
Robust Product Pipeline
Angiochem’s novel pharmaceuticals are currently being investigated in a number of
preclinical and clinical studies, and have been published in several scientific publications.
EPiC: The Proprietary, Proven Technology Platform
The blood-brain barrier (BBB) prevents foreign substances, including more than 95% of drugs, from reaching the brain. But Angiochem’s drugs are different.
These innovative products are engineered from the highly versatile and proprietary EPiC (Engineered Peptide Compounds) platform technology, which utilizes the BBB’s own receptors, specifically the lipoprotein receptor-related protein (LRP-1) receptor, to gain entry into the brain. This approach has been validated in several clinical trials and scientific publications.1-4
View an animation showing EPiC Technology in action and see how how Angiochem’s pharmaceuticals penetrate the blood-brain barrier.
- Deeken JF, Löscher W. The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses Clin Cancer Res 2007;13: 1663-74.
- Schinkel AH. P-Glycoprotein, a gatekeeper in the blood–brain barrier. Advanced Drug Delivery Reviews 1999;36: 179–194.
- Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacology & Therapeutics 2004; 104: 29– 45.
- Jones ER, Shusta EV. Blood-Brain Barrier Transport of Therapeutics via Receptor-Mediation. Pharm Res. 2007; 24: 1759–1771.